aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased sales forecast for the financial year 2012 to EUR 34 million (+16%)
(Thomson Reuters ONE) -
aap Implantate AG /
aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased
sales forecast for the financial year 2012 to EUR 34 million (+16%)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG, a medical technology company listed in the Frankfurt Stock
Exchange's Prime Standard segment, generated EUR 9.9 million in sales (previous
year: EUR 6.5 million) in the first three months of financial year 2012, which
was a 51% increase on the previous year's first quarter. This strong sales
growth was due mainly to an 18% increase in product sales to EUR 7.7 million
(previous year: EUR 6.5 million) and to revenue from the conclusion of an
exclusive license agreement worth EUR 2.2 million with a world-leading medical
technology company. EBITDA increased to EUR 2.1 million (previous year: EUR 0.8
million).
+---------------------+------------+------------+--------+
| In EUR million | Q1/2012 | Q1/2011 | Change |
+---------------------+------------+------------+--------+
| Sales | 9.9 | 6.5 | +51% |
+---------------------+------------+------------+--------+
| Product sales | 7.7 | 6.5 | +18% |
+---------------------+------------+------------+--------+
| EBITDA | 2.1 | 0.8 | >100% |
+---------------------+------------+------------+--------+
| EBIT | 1.3 | 0.1 | >100% |
+---------------------+------------+------------+--------+
| Cash-EBIT | 1.0 | -0.4 | n. a. |
+---------------------+------------+------------+--------+
| In EUR million | 3/31/2012 | 12/31/2011 | Change |
+---------------------+------------+------------+--------+
| Equity (ratio) | 49.4 (74%) | 48.4 (73%) | 2% |
+---------------------+------------+------------+--------+
| Balance sheet total | 67.1 | 66.2 | 1% |
+---------------------+------------+------------+--------+
| Employees FTE* | 247 | 251 | -2% |
+---------------------+------------+------------+--------+
*Full-Time-Equivalents (FTE) are the number of full-time employed persons during
a period
In the first quarter of 2012 aap Group's EBIT was EUR 1.3 million (previous
year: EUR 0.1 million) and its EBT amounted to EUR 1.2 million (previous year:
EUR 0.1 million). On a balance sheet total of EUR 67.1 million (31.12.2011:
EUR 63.4 million) the equity ratio was 74%.
In the first quarter, aap presented its innovative LOQTEQ® product line to
potential new distributors in Europe, the United States, Asia and Latin America,
while the centre of excellence for trauma in Berlin continued to work on the FDA
approval of the LOQTEQ® product family. aap expects to receive full FDA approval
on the LOQTEQ® product line in the third quarter of 2012. The center of
excellence for contract manufacturing in Nijmegen signed in the first quarter a
contract to process human tissue with the Dutch Sanquin bone and tissue bank.
Outlook for 2012
On the basis of the positive result for the first quarter, the current order
intake and potential new customer relationships, aap Implantate AG is revising
its sales forecast for the financial year 2012. The Management Board now
anticipates total sales of around EUR 34 million (previous forecast: around EUR
32 million), or 16% sales growth on the previous year.
The main strategic focus in the financial year 2012 will be on the core business
segments trauma and bone cement and cementing techniques, in which aap aims to
achieve double-digit sales growth and a positive Cash-EBIT. Sales growth is to
be realised through the launch of the innovative LOQTEQ® product line and its
FDA approval along with further strong sales growth in the bone cement and
cementing techniques segment, license business, OEM contracts and another
project deal.
aap Implantate AG's full report for the first quarter of 2012 is available for
you to download at www.aap.de.
This release contains forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich(at)aap.de
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1612106]
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2012 - 08:27 Uhr
Sprache: Deutsch
News-ID 146400
Anzahl Zeichen: 7253
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap reports profitable Q1 2012 sales growth of 51% to EUR 9.9 million; Increased sales forecast for the financial year 2012 to EUR 34 million (+16%)"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
